Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability and Efficacy of RZ-001 in Combination with Valganciclovir in Subjects with Hepatocellular Carcinoma

NCT05595473 is registered in ClinicalTrials.gov with Rznomics, Inc. as lead sponsor.

NCT NCT05595473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05595473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability and Efficacy of RZ-001 in Combination with Valganciclovir in Subjects with Hepatocellular Carcinoma
Lead sponsor
Rznomics, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 29, 2022
Completion date
May 31, 2029
Enrollment
42 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma